By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Janssen Pharmaceutica N.V. 

Turnhoutseweg 30

Beerse  Antwerpen  2340  Belgium
Phone: 32-14602226 Fax:




Vertex  (telaprevir for HCV) - Europe, South America, Australia, the Middle East and other countries

Company News
Royal Philips Electronics N.V. (PHG) Enters Into Collaboration With Janssen Pharmaceutica N.V. To Develop New Handheld Blood Test To Support Care Of Patients With Neuropsychiatric Disorders 3/25/2015 1:56:23 PM
Galapagos (GLPG.BR) Ends Long-Running R&D Inflammation Pact With Janssen Pharmaceutica N.V. 3/17/2015 6:07:57 AM
EB Pharma Announces License Agreement For Investigational Drug, Tipifarnib From Janssen Pharmaceutica N.V. For Development In Hepatitis Delta Virus (HDV) Infection 12/23/2014 7:51:48 AM
Galapagos NV (GLPG.BR) Initiates Phase 1 Study With GLPG1690, Triggering €6.6 M Milestone In The Alliance With Janssen Pharmaceutica N.V. 7/1/2014 9:13:37 AM
Janssen Pharmaceutica N.V. To Present New Simeprevir Data At The International Liver Congress™ 2014 Of The European Association For The Study Of The Liver (EASL) 3/24/2014 9:49:06 AM
Janssen Pharmaceutica N.V. Release: New Data Show XEPLION® Significantly Delays Time To Relapse Compared To Treatment As Usual With Oral Antipsychotic Monotherapy 3/4/2014 9:59:54 AM
Jubilant BioSys Ltd. Announces Expansion Of Drug Discovery Alliance With Janssen Pharmaceutica N.V. 2/19/2014 7:14:37 AM
Janssen Pharmaceutica N.V. Unveils New Data On Xeplion® In Various Stages Of Schizophrenia 12/1/2013 10:02:42 PM
Galapagos NV (GLPG.BR) Initiates Phase 1 Trial as Part of Its Alliance With Janssen Pharmaceutica N.V. 7/2/2013 10:43:47 AM
Janssen Pharmaceutica N.V., Funds New Global Mental Health Scholarships as Part of Its Healthy Minds Program 3/5/2013 1:09:43 PM